- Home
- KDK vs COGT Comparison
KDK vs COGT Comparison
Compare KDK & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KDK
- COGT
- Stock Information
- Founded
- KDK 2018
- COGT 2014
- Country
- KDK United States
- COGT United States
- Employees
- KDK N/A
- COGT N/A
- Industry
- KDK EDP Services
- COGT Biotechnology: Pharmaceutical Preparations
- Sector
- KDK Technology
- COGT Health Care
- Exchange
- KDK Nasdaq
- COGT Nasdaq
- Market Cap
- KDK 1.3B
- COGT 1.1B
- IPO Year
- KDK N/A
- COGT 2018
- Fundamental
- Price
- KDK $8.00
- COGT $15.52
- Analyst Decision
- KDK
- COGT Strong Buy
- Analyst Count
- KDK 0
- COGT 11
- Target Price
- KDK N/A
- COGT $21.20
- AVG Volume (30 Days)
- KDK 2.1M
- COGT 2.1M
- Earning Date
- KDK 11-15-2025
- COGT 11-11-2025
- Dividend Yield
- KDK N/A
- COGT N/A
- EPS Growth
- KDK N/A
- COGT N/A
- EPS
- KDK N/A
- COGT N/A
- Revenue
- KDK N/A
- COGT N/A
- Revenue This Year
- KDK N/A
- COGT N/A
- Revenue Next Year
- KDK N/A
- COGT N/A
- P/E Ratio
- KDK N/A
- COGT N/A
- Revenue Growth
- KDK N/A
- COGT N/A
- 52 Week Low
- KDK $5.77
- COGT $3.72
- 52 Week High
- KDK $10.48
- COGT $16.22
- Technical
- Relative Strength Index (RSI)
- KDK N/A
- COGT 71.71
- Support Level
- KDK N/A
- COGT $13.72
- Resistance Level
- KDK N/A
- COGT $16.22
- Average True Range (ATR)
- KDK 0.00
- COGT 0.69
- MACD
- KDK 0.00
- COGT 0.24
- Stochastic Oscillator
- KDK 0.00
- COGT 85.02
About KDK Kodiak AI Inc. Common Stock
Kodiak AI Inc is engaged in the commercial trucking industry and the public sector, based on AI-powered autonomous vehicle technology.
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.